Federal Contractor Profile
Partner Therapeutics, INC.
Federal contracting record: $258M obligated across 15 awards from 2 agencies, FY 2018–2026.
Company Profile
Parent UEI (Unique Entity Identifier)
J33MSDBJZMC6
CAGE Code
7ZTL0
Address
ONE MARINA PARK DR, STE 900, BOSTON, MA, 022101881
First Federal Award
Apr 25, 2018
Most Recent Award
Jun 16, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$258M
99.9% of total obligations
- Department of Veterans Affairs$163K
0.1% of total obligations
Top NAICS Activity
- $248M
- 541715$13M
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
1 awards
- $1.5M
- -$4.0M
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Sep 4, 2026 | Department of Veterans Affairs246-NETWORK CONTRACTING OFFICE 6 (36C246) | 325412 | BIZENGRI MEDICATION | $72K |
| Jun 16, 2026 | Department of Veterans Affairs246-NETWORK CONTRACTING OFFICE 6 (36C246) | 325412 | EMERG. BIZENGRI MEDS FOR VETERAN | $73K |
| Jun 10, 2026 | Department of Health and Human ServicesASPR/ORM-SNS | 325412 | LEUKINE 250MCG VIL INJ (5PKG) | $34M |
| May 5, 2026 | Department of Veterans Affairs246-NETWORK CONTRACTING OFFICE 6 (36C246) | 325412 | EMERGENCY BIZENGRI MEDS. FOR VETERAN | $54K |
| Apr 10, 2026 | Department of Veterans Affairs246-NETWORK CONTRACTING OFFICE 6 (36C246) | 325412 | EMERGENCY BIZENGRI MEDS FOR VETERAN | $36K |
| Mar 26, 2026 | Department of Health and Human ServicesASPR/ORM-SNS | 325412 | LEUKINE 250MCG VIL INJ (5PKG) | $16M |
| May 15, 2025 | Department of Health and Human ServicesASPR/ORM-SNS | 325412 | LEUKINE 250MCG VIL INJ (5PKG) | $20M |
| Nov 6, 2024 | Department of Health and Human ServicesASPR/ORM-SNS | 325412 | LEUKINE 250MCG VIL INJ (5PKG) | $19M |
| Sep 24, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541715 | PARTNER THERAPEUTICS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO CONFIRM LEUKINE SAFETY IN SEPSIS PATIENTS, INFORM OPTIMAL LEUKINE DOSING, EXPLORE LEUKINE EFFICACY, AS WELL AS ADVANCE DEVELOPMENT OF MONOCYTE HUMAN LEUKOCYTE ANTIGEN-DR (MHLA-DR) AS | $13M |
| Aug 5, 2024 | Department of Health and Human ServicesASPR/ORM-SNS | 325412 | LEUKINE 250MCG VIL INJ (5PKG) | $22M |
| Sep 26, 2023 | Department of Health and Human ServicesASPR/ORM-SNS | 325412 | LEUKINE 250MCG VIL INJ (5PKG) | $22M |
| Sep 25, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | R&D FOR REPURPOSING FX06, A HOST-DIRECTED THERAPY, FOR TREATMENT OF SEVERE DISEASE IN PATIENTS WITH SUDAN VIRUS DISEASE (SVD) OR OTHER FILOVIRUSES AOI #22 REBOOT | $748K |
| Jul 25, 2022 | Department of Health and Human ServicesASPR/ORM-SNS | 325412 | LEUKINE 250MCG/VIL INJ | $59M |
| Sep 30, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 325414 | IGF::OT::IGF FOR OTHER FUNCTIONS PROJECT: ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION (RTOR-CSF-0003) | $2K |
| Sep 2, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PARTNER THERAPEUTICS, INC.: .: BARDA DRIVE : RESEARCH AND DEVELOPMENT OF DIAGNOSTIC TESTS FOR PATIENTS WITH SEPSIS AND IMMUNOPARALYSIS | $749K |
| Sep 16, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 325412 | LEUKINE 250MCG/VIL INJ 186,440 | $55M |
Want to win work like Partner Therapeutics, INC.?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.